Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis.

Trial Profile

Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2012

At a glance

  • Drugs Insulin; Insulin aspart; Insulin aspart
  • Indications Diabetic ketoacidosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2012 Actual end date (1 Dec 2007) added as reported by ClinicalTrials.gov.
    • 15 Aug 2012 Actual initiation date (1 Jan 2005) added as reported by ClinicalTrials.gov.
    • 23 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top